You have 9 free searches left this month | for more free features.

Relapsed and refractory peripheral T-cell lymphoma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Fairport (Tolinapant, Decitabine + Cedazuridine)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Aurora, Colorado
  • +2 more
Jan 3, 2023

T-cell Lymphoma Patients After First-line Treatment Failure Trial (SHR2554; Chidamide analog tablets, SHR2554 analog tablets;

Not yet recruiting
  • T-cell Lymphoma Patients After First-line Treatment Failure
  • SHR2554; Chidamide analog tablets
  • SHR2554 analog tablets; Chidamide
  • (no location specified)
Nov 5, 2023

Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)

Recruiting
  • Peripheral T Cell Lymphoma
  • Azacitidine Injection
  • +6 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Suzhou (Anti-PD-1 mAb, Lenalidomide, Azacitidine)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Anti-PD-1 monoclonal antibody
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 21, 2021

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides Trial in United

Recruiting
  • Folliculotropic Mycosis Fungoides
  • +7 more
  • Durvalumab
  • +2 more
  • Duarte, California
  • +3 more
Jan 12, 2023

Treatment, Peripheral T-cell Lymphoma Trial in Beijing (liposomal mitoxantrone HCl, gemcitabine, dexamethasone, and cisplatin)

Recruiting
  • Treatment
  • Peripheral T-cell Lymphoma
  • liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
  • Beijing, China
  • +4 more
Jun 28, 2022

Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 2, 2023

Peripheral T-Cell Lymphoma Trial in Zhengzhou (Parsaclisib, Chidamide)

Not yet recruiting
  • Peripheral T-Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Dec 26, 2021

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma
  • Kaohsiung, Taiwan
  • +4 more
Apr 17, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)

Not yet recruiting
  • Relapsed or Refractory T-cell Lymphomas
  • Sendai-shi, Miyagi, Japan
    Local Institution - 0001
Sep 12, 2023

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Peripheral T-cell Lymphoma Trial in Beijing (AK104)

Terminated
  • Peripheral T-cell Lymphoma
  • AK104
  • Beijing, Beiing, China
    Beijing Cancer Hospital
Oct 17, 2022

T Cell Lymphoma Trial (Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen)

Not yet recruiting
  • T Cell Lymphoma
  • Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
  • (no location specified)
Mar 6, 2023

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Peripheral T-cell Lymphoma Trial in Shanghai (PD-1 antibody+ HDAC inhibitor)

Recruiting
  • Peripheral T-cell Lymphoma
  • PD-1 antibody+ HDAC inhibitor
  • Shanghai, Shanghai, China
    Dongmei Ji
Dec 3, 2021

Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Cutaneous T-cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 8, 2023

Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • Fungoides Mycosis Sezary Syndrome
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center
Jul 13, 2023

NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

Not yet recruiting
  • NK/T Cell Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
  • +1 more
Jan 12, 2023

Peripheral T/NK Cell Lymphoma (R/R PTCL) Trial (YY-20394)

Recruiting
  • Peripheral T/NK Cell Lymphoma (R/R PTCL)
  • Houston, Texas
    MD Anderson Cancer Center
Oct 19, 2022